Tag: equity
-
Peanut Allergy Therapy Company Raises $160 Million in IPO
6 August 2015. Aimmune Therapeutics Inc., a developer of treatments for peanut and other food allergies, raised $160 million from its initial public stock offering, pricing its 10 million shares at $16.00. Shares in the Brisbane, California company trade on the Nasdaq exchange under the symbol AIMT. Shares closed today (6 August), priced at $24.10…
-
Allergan Acquires Depression Therapy Developer for $560M
27 July 2015. Pharmaceutical maker Allergan plc is acquiring Naurex Inc., a designer of fast-acting therapies for depression and other neurological disorders, for $560 million. The deal covers Naurex’s products now in clinical trials, with the company’s technology platform and preclinical research spun-off into a new enterprise. Naurex, a spin-off company from Northwestern University in…
-
Drug Delivery Biotech Raises $101.8 Million in IPO
17 July 2015. Chiasma Inc., a biotechnology enterprise developing oral therapies to replace injected drugs, raised some $101.8 million in its initial public stock offering. The company — located in Newton, Massachusetts and Jerusalem, Israel — issued 6,365,000 shares at $16.00, and trades on the Nasdaq exchange under the symbol CHMA. Shares in the company closed…
-
Juno, Celgene Partner in $1 Billion Immunotherapy Deal
30 June 2015. Biotechnology company Juno Therapeutics Inc. and biopharmaceutical developer Celgene Corp. are collaborating on therapies that harness the immune system to treat cancer and autoimmune diseases over the next 10 years. The agreement is expected to bring Juno nearly $1 billion from Celgene in upfront payments and stock purchases. Juno Therapeutics, headquartered in…
-
Novartis Acquires Pain Medication Developer in $200M Deal
29 June 2015. Global pharmaceutical company Novartis is acquiring Spinifex Pharmaceuticals Inc., a developer of new types of therapies for neuropathic pain. Spinifex reports Novartis is paying $200 million in cash for the company — based in Stamford, Connecticut and Melbourne, Australia — as well as undisclosed future milestone payments. Spinifex Pharmaceuticals develops therapies for…
-
Rare Disease Therapy Company Raises $60 Million in IPO
26 June 2015. Catabasis Pharmaceuticals Inc., a biotechnology company creating treatments for rare diseases and cholesterol-related disorders, is raising $60 million in its initial public stock offering, trading on the Nasdaq exchange under the symbol CATB. The Cambridge, Massachusetts enterprise yesterday priced its 5 million shares at $12.00, and as of 4:00 pm today is…
-
Smartphone Eye Exam Company Raises $6M in Venture Funds
24 June 2015. Smart Vision Labs Inc., a two-year-old company developing vision exam technology that works on smartphones, raised $6.1 million in its first venture funding round. Financing for the New York City enterprise was led by Techstars Ventures, with contributions from Heritage Group, Connectivity Capital, and Red Sea Ventures. The company’s technology aims to…
-
Intel Begins $125M Diversity Investment Fund
10 June 2015. The venture capital division of semiconductor manufacturer Intel unveiled a fund to invest in technology start-ups founded by women and under-represented minorities. Intel Capital announced as well the first four investments from its Capital Diversity Fund, which expects to distribute some $125 million over the next 5 years. Intel cited data showing…
-
Biotech Adds Antibiotic Program, Raises $30 Million
8 June 2015. Spero Therapeutics, a developer of antibiotics, is adding a new class of anti-infection drugs to its pipeline, and raised another $30 million to its first venture funding round. The Cambridge, Massachusetts biotechnology company, a spin-off from Massachusetts General Hospital in Boston, was founded in April 2014 to develop therapies addressing the growing…
-
Life Sciences Commercialization Firm to Crowdfund IPO
4 June 2015. Innovation Economy Corporation is going public by skipping the usual route of hiring an investment bank, and instead will use crowdfunding to attract investors to its initial public offering of stock. The Riverside, California enterprise, that goes by the trade name ieCrowd, licenses life science and health-related technologies from university research labs…